SGO Meeting Highlights via Twitter ~ Day Two, March 13, 2017

More news from the The Society of Gynecologic Oncology (@SGO_org) Annual Meeting. I am at home and have been following Tweets from the meeting using the hashtag #SGOmtg.

Here are some tweets I found of interest today-  Monday, March 13th.

Endometrial Cancer:

More evidence that molecular/genetic makeup of endometrial CA in blacks explains poorer prognostic factors #SGOMtg

— A.C. Evans, MD, PhD (@gynoncdoc) March 13, 2017

Maxwell: High MS7 levels in primary tumor consistently associated with poor outcome in endometrial cancer. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Great study from @SArmbrusterMD: physical activity intervention associate w long term wt loss in EC pts at meet the prof #SGOMtg #endcancer

— Katie Kurnit (@katiekurnit) March 13, 2017

Burnout in Gynecologic  Oncologists

Dr. Fowler discussing strategies to address burnout. #SGOMtg #selfcare pic.twitter.com/AZ3SnRhUKW

— Shannon Armbruster (@SArmbrusterMD) March 13, 2017

Fowler Prez Addrs: Physician wellness=Better patient outcomes & Quality care. #SGOMtg We NEED you & we need you 2 take care of yourselves ❤

— Annie Ellis (@Stigetta) March 13, 2017

Patient Centered Assessment Tool - Great work done by my friend and fellow advocate Annie Ellis.

Poster 94: Priorities assessment tool (PAT) to support shared decision making, maximize appt time & increase patient satisfaction #SGOMtg pic.twitter.com/Kj7d1oa46M

— Annie Ellis (@Stigetta) March 13, 2017

IP Chemotherapy

OV21/PETROC trial. another trial that shows intraperitoneal chemotherapy for #ovariancancer patients is better. #SGOMtg #fightsmarter

— Rod Rocconi (@rodrocconi) March 13, 2017

Poster 148: no sig diff b/w bev and IP chemo in PFS or OS in pts with #BRCA positive #ovariancancer #SGOMtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Circulating DNA

ctDNA is the future of precision oncology for GYN patients and beyond! So many possibilities! #SGOMtg #endCancer

— Katie Kurnit (@katiekurnit) March 13, 2017

 Niraparib

Today we presented secondary endpoint data from our landmark NOVA trial at #SGOMtg. Read our press release for more: https://t.co/l9Hk9HULIa

— TESARO, Inc. (@TESAROBIO) March 13, 2017

Maintenance niraparib improved outcomes & not detrimental to QoL in heavily pretreated platinum sensitive gBRCAmut and non-gBRCAmut #SGOMtg pic.twitter.com/RGkJxDSkod

— Annie Ellis (@Stigetta) March 13, 2017

 Rucaparib

Latest updates for rucaparib for #ovariancancer in ARIEL2 trial , presented at @SGO_org #SGOMtg : https://t.co/ONXf5WtfMg pic.twitter.com/9TfNQoQ0wu

— ecancer (@ecancer) March 13, 2017

Genetic Testing

As we discuss genetic testing at #SGOMtg, important to remember the personal implications https://t.co/5KbrWG7NCw #ovarian cancer #gyncsm

— Dr. Robert Dood (@DrRobDood) March 13, 2017

 GPI -  Glucose-6-phosphate isomerase

Previs: High GPI levels in patients w ovca associated with worse prognosis. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Previs: GPI: glucose 6-phosphate isomerase. Previs finds that inhibition associated with more cell kill/less tumor burden. #SGOMtg

— Don S Dizon (@drdonsdizon) March 13, 2017

Neoadjuvant Chemotherapy

R Arend: NACT for #ovariancancer leads to upregulation of #DNA damage repair pathway genes #sgomtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Arend: pt w/ #BRCA mutation had lowest DNA damage pathway score after NACT - further investigation needed #sgomtg

— Myriad myChoice (@MyriadMyChoice) March 13, 2017

Slides from a Sunday presentation on  PARP

Drs. Coleman, Herzog, @DrMatulonis, @ShannonWestin Downloadable Slides Now Available at https://t.co/FOiuvBPJzG from symposium at #SGOMtg pic.twitter.com/OChFoann3G

— BioAscend (@BioAscend) March 13, 2017

Thanks for all those tweeting from the meeting especially these folks

Follow the newest #socialmedia stars from @mdandersonnews 4 #gyncancer #SGOMtg updates @DrRobDood @katiekurnit @JDottinoMD @RTylerHillmanMD https://t.co/mVo1TZBt9D

— Shannon Westin (@ShannonWestin) March 13, 2017

Tweeting. #SGOMtg #gyncsm pic.twitter.com/dNrDqpZxut

— Robert Tyler Hillman (@RTylerHillmanMD) March 13, 2017

Looking forward to Tweets from tomorrow's meeting.

Dee Every Day is a Blessing!

Hipec treatment

Hipec = Hyperthermic interperitoneal chemotherapy

On August 11th , the NY Times published an article discussing surgery and hyperthermic interperitoneal chemotherapy for appendix, colon and ovarian cancers. The article

Hot Chemotherapy Bath: Patients See Hope, Critics Hold Doubts includes photos of the invasive surgery.

After reading the entire article and looked at the photos I have some concerns. There has only been one clinical trial ( 10 years ago) using this process for appendix cancer. What dosages of chemotherapy are the doctors using? In the case of ovarian cancer, is the dosage the same as that used in interperitoneal therapy? Is the temperature they are heating the chemo to the optimum level? Is one chemo drug better than another? Will patients still need to have IV chemo after the treatment? Would heating IP chemotherapy drugs ( since there are numerous clinical trials with this process) have the same result as this flushing process?

There are many unanswered questions and I hope there are plans to design some trials to answer those questions.

Dee

Every Day is a Blessing!